Tools and reagent companies at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
58 tools and reagent companies are at ESGCT 2026 — 136 presentations on the program. Most represented: Cytiva (8 on the program), Merck KGaA (7 on the program), Sartorius (5 on the program). 37 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–4 of 58 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
Cytiva Marlborough, Massachusetts | |
Supplies bioprocessing equipment, consumables and cell therapy manufacturing systems used to develop and produce biologics and cell and gene therapies. | Poster Wed Oct 28 1:30pm–3:30pm A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies Poster Wed Oct 28 1:30pm–3:30pm Application-Driven Optimization of Tangential Flow Filtration for Extracellular Vesicle Manufacturing Poster Wed Oct 28 1:30pm–3:30pm Design and development of an integrated and automatic multi-step chromatography workflow for AAV purification. Poster Wed Oct 28 1:30pm–3:30pm From transient screening to stable production: a modular platform enabling accelerated, scalable and quality‑driven AAV manufacturing Poster Wed Oct 28 1:30pm–3:30pm Next-generation AAV9 affinity resin for improved yield, speed, and scalability Poster Wed Oct 28 1:30pm–3:30pm Scalable in vitro transcription using the WAVE 25 bioreactor system and Cytiva enzyme microreactor accessory Talk Thu Oct 29 1:30pm–2:30pm Solid tumors across modalities: Early decisions that shape the path to patient Cancer gene and cell therapyManufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm Accelerating Stable AAV Producer Cell Line Development Through AI-Driven Decision Intelligence Poster Thu Oct 29 2:00pm–4:00pm Redefining the Cost Equation for AAV Manufacturing: ELEVECTA™ 2.0 reshapes stable production economics Poster Thu Oct 29 2:00pm–4:00pm Synergizing Nanoplasmid vector technology and ELEVECTA™ transient cell line to improve AAV quality Poster Thu Oct 29 2:00pm–4:00pm Towards a universal lipid nanoparticle (LNP) platform for multiplex engineering of next- generation ex vivo cell therapies |
Merck KGaA Darmstadt, Germany | |
Science and technology group whose life science business supplies bioprocessing products, testing services and contract manufacturing for viral vectors. | Poster Wed Oct 28 1:30pm–3:30pm A scalable platform solution for AAV production from 3 L to 1000 L scale Poster Wed Oct 28 1:30pm–3:30pm Cation-Exchange Membrane Chromatography as a Non-Affinity Capture Strategy for Recombinant AAV Poster Wed Oct 28 1:30pm–3:30pm Characterization of viral proteins in adeno-associated virus for gene therapy using Capillary Electrophoresis (CE) Poster Wed Oct 28 1:30pm–3:30pm Evaluation of an upstream platform for efficient lentiviral vector manufacturing Poster Wed Oct 28 1:30pm–3:30pm Fast and reliable PAT-Raman model establishment for upstream monitoring of AAV production Poster Wed Oct 28 1:30pm–3:30pm From Bench to Pilot: Leveraging Platform Approaches for Seamless Scale-up of AAV Production Poster Wed Oct 28 1:30pm–3:30pm Structure-Activity-Relationship (SAR) study to characterize the cause of the thermo-induced potency reduction of adeno-associated virus for gene therapy Poster Wed Oct 28 1:30pm–3:30pm Viral vector characterization using field-flow fractionation coupled with multi-angle light scattering and dynamic light scattering (FFF-MALS-DLS) Manufacturing, CMC and access Poster Thu Oct 29 2:00pm–4:00pm Identifying and overcoming process and titer variability during HEK293 AAV production Poster Thu Oct 29 2:00pm–4:00pm Intensified AAV9 purification using novel, highly selective, caustic stable affinity capture Poster Thu Oct 29 2:00pm–4:00pm Optimization of baculovirus expression vector system to produce AAV8 in Sf9 derived insect cells Poster Thu Oct 29 2:00pm–4:00pm Using Next Generation Sequencing (NGS) as part of your potency assurance strategy for AAVs. |
Sartorius Göttingen, Germany | |
Supplies bioprocess equipment, consumables and lab instruments used to develop and manufacture biologics, including viral vectors for gene therapy. | Poster Wed Oct 28 1:30pm–3:30pm Artificial promoters designed to enhance GT bioprocesses Poster Wed Oct 28 1:30pm–3:30pm Chromatography-Based Downstream Processing of Imidazole-based Cationic Lipid Nanoparticles: Evaluating Process Productivity and Functional Performance Poster Wed Oct 28 1:30pm–3:30pm Development of a High-Yield AAV Production Platform Using DOE and Automated Bioreactors Talk Wed Oct 28 1:30pm–2:30pm Translating AAV Innovation into Therapeutic Reality: Perspectives from a Developer, Technology Innovator, and CDMO Manufacturing, CMC and accessVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Innovative Imidazolium-Based Lipids Fuel Next-Generation LNPs for Targeted Oncology and Advanced Cell Therapies Poster Thu Oct 29 2:00pm–4:00pm Innovative Lipid-Based Preformed Vesicle (PFV) Solution: Unlocking New Opportunities for the Manufacturing of Autologous and Allogeneic CAR-T and NK Cells Poster Thu Oct 29 2:00pm–4:00pm Looking in or looking out: Do extracellular metabolites tell enough for AAV production design? Poster Thu Oct 29 2:00pm–4:00pm Maximizing HEK293 Productivity: Process Intensification via HCD Transfection Poster Thu Oct 29 2:00pm–4:00pm Optimization of clarification conditions for lentiviral vectors Poster Thu Oct 29 2:00pm–4:00pm Optimizing HEK suspension readaptation and clone selection to reduce aggregation and improve rAAV production |
Miltenyi Biotec Bergisch Gladbach, Germany | ◆Gold Sponsor |
Cell separation pioneer providing instruments, reagents and process development services for cell and gene therapies in cancer, autoimmune and inherited disease. | Poster Wed Oct 28 1:30pm–3:30pm TCR T cells manufactured using a CD8-targeted lentiviral vector Poster Thu Oct 29 2:00pm–4:00pm Armoring GD2-targeted CAR T cells with anti-CD39 activity-blocking nanobodies. Poster Thu Oct 29 2:00pm–4:00pm Automated ex vivo processing enhances lentiviral transduction and preserves stemness processing enhances lentiviral transduction and preserves stemness in human cd34⁺ hematopoietic stem cells Poster Thu Oct 29 2:00pm–4:00pm Development of a GMP-compliant automated hematopoietic stem cell engineering process for pediatric and adult use cases Poster Thu Oct 29 2:00pm–4:00pm Targeted Lentiviral Vectors for Gene Transfer in vivo Poster Thu Oct 29 2:00pm–4:00pm Towards scalable Point-Of-Care HSC gene therapy through automated lipid nanoparticle engineering of CD34+ cells |
Instantly find 20 buyers from tools and reagent companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction